Diagnostic Odyssey: Whole Genome Sequencing (WGS) (NCT03458962)
Ending the Diagnostic Odyssey: Whole Genome Sequencing (WGS) to Identify Genetic Determinants of Previously Undiagnosed Disease in Children
🩺 Plain-English Summary (8th-Grade Level)
The goal of this collaborative research is to study human genomes in children with suspected congenital disease, multiple-congenital anomalies and/or multi-organ disease of unknown etiology by understanding the potential value of Whole Genome Sequencing (WGS) in establishing genetic diagnosis. The study will examine diagnosis rates, changes in clinical care as a result of a genetic diagnosis, health economics including potential cost-effectiveness of WGS and patient and provider experience with genomic medicine.
Who can join: Review the eligibility criteria below.
Location: Nickalus Children's Hospital f/k/a Miami Children's Hospital — Miami, Florida
Age range: Not specified to 21 Years
🧪 Interventions in This Study
- Genetic Enrollees (GENETIC)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Nickalus Children's Hospital f/k/a Miami Children's Hospital — Miami, Florida
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Genetic Disease
- Clinical Decision Support to Identify Pediatric Patients With Undiagnosed Genetic Disease — Nashville, Tennessee
- The Electronic Medical Records and GEnomics (eMERGE) Network Genomic Risk Assessment — Birmingham, Alabama
- Penn Medicine Biobank Return of Results Program — Philadelphia, Pennsylvania
- An Open-label, Single Center, Single Participant Study of an Experimental Antisense Oligonucleotide Treatment for TUBB4A-related Leukodystrophy — San Diego, California
- Personalized Antisense Oligonucleotide Therapy for Rare Pediatric Genetic Disease: SCN2A — San Diego, California
Explore by condition: All Genetic Disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.